H.U. Group Holdings Inc. and its subsidiary Fujirebio have announced the launch of the Lumipulse G sTREM2 assay, a ...

Fujirebio collaborates with Stanford Medicine to advance research and innovation in the field of infectious disease testing: Tokyo, Japan Saturday, June 7, 2025, 13:00 Hrs [IST] F ...

The U.S. Food and Drug Administration has approved the marketing of a new tool to that can test a person’s blood to diagnose ...

The partners will work together to explore the use of a technology from Fujirebio subsidiary Fluxus in infectious disease.

Malvern biotechnology company Fujirebio Diagnostics has developed a revolutionary new test to diagnose Alzheimer’s disease, writes Harold Brubaker for ...

Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the ...

Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years' accumulated experience in the ...

PALO ALTO, CALIFORNIA / ACCESS Newswire / May 28, 2025 / Bioz, Inc., a global leader in AI-powered scientific citation management, is proud to collaborate with Fujirebio, further strengthening its com ...

PALO ALTO, CALIFORNIA / ACCESS Newswire / May 28, 2025 / Bioz, Inc., a global leader in AI-powered scientific citation ...

The Malvern location of Fujirebio Diagnostics Inc.’s played key role in the clinical development of the first FDA-approved ...

The test allows for much earlier detection of the disease, even before clear memory or behavioural symptoms appear ...